Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Irene Bagaloni"'
Autor:
Irene Bagaloni, Axel Visani, Sara Biagiotti, Annamaria Ruzzo, Mohsen Navari, Maryam Etebari, Lucia Mundo, Massimo Granai, Stefano Lazzi, Alessandro Isidori, Federica Loscocco, Jiejin Li, Lorenzo Leoncini, Giuseppe Visani, Mauro Magnani, Pier Paolo Piccaluga
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Altered cellular energetic metabolism has recently emerged as important feature of neoplastic cells. Indeed, interfering with cancer cell metabolism might represent a suitable therapeutic strategy. In this study, we aimed to assess glucose metabolism
Externí odkaz:
https://doaj.org/article/305e9d07524b48dba08c61891a543639
Autor:
Federica Loscocco, Giuseppe Visani, Annamaria Ruzzo, Irene Bagaloni, Fabio Fuligni, Sara Galimberti, Antonello Di Paolo, Fabio Stagno, Patrizia Pregno, Mario Annunziata, Antonella Gozzini, Sara Barulli, Elisa Gabucci, Mauro Magnani, Alessandro Isidori
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of
Externí odkaz:
https://doaj.org/article/43ad989d92e946a3a061a8934831529a
Autor:
Alberto Sobrero, Nicoletta Pella, Mauro Magnani, Maria Teresa Ionta, Pietro Sozzi, Vittorina Zagonel, Luisa Foltran, Francesco Graziano, Roberto Labianca, Silvia Lazzarelli, Monica Ronzoni, Enzo Veltri, Annamaria Ruzzo, Francesca Bergamo, Daniele Turci, Eliana Rulli, Luciano Frontini, Claudio Verusio, Sandro Barni, Claudia Mucciarini, Edoardo Biondi, Vincenzo Ricci, M. Nicolini, Annalisa Bramati, Sara Lonardi, Bruno Massidda, Francesca Galli, F. Galli, Irene Bagaloni
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
Scientific Reports
Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II
Autor:
Sara Barulli, Fabio Fuligni, Mauro Magnani, Elisa Gabucci, Alessandro Isidori, Mario Annunziata, Antonello Di Paolo, Federica Loscocco, Giuseppe Visani, Annamaria Ruzzo, Antonella Gozzini, Fabio Stagno, Patrizia Pregno, Irene Bagaloni, Sara Galimberti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a21c9d49b5b13a50539668df92d90899
https://www.frontiersin.org/articles/10.3389/fonc.2021.672287/full
https://www.frontiersin.org/articles/10.3389/fonc.2021.672287/full
Autor:
Alberto Sobrero, M. Nicolini, Sara Lonardi, Nicoletta Pella, F. Galli, Irene Bagaloni, Edoardo Biondi, Bruno Massidda, Luciano Frontini, Mauro Magnani, Enzo Veltri, Maria Teresa Ionta, Francesca Bergamo, Eliana Rulli, Annalisa Bramati, Sandro Barni, Monica Ronzoni, Claudia Mucciarini, Francesca Galli, Silvia Lazzarelli, Annamaria Ruzzo, Daniele Turci, Francesco Graziano, Roberto Labianca, Vittorina Zagonel, Claudio Verusio, Luisa Foltran, Vincenzo Ricci, Pietro Sozzi
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-1 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-1 (2020)
Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II
Autor:
Nicholas W. Fischer, Michela Del Prete, Giuseppe Perrone, Maria Di Bartolomeo, Elena Ongaro, Paolo Alessandroni, Mauro Magnani, Francesco Graziano, R. Bisonni, D. Sarti, David Malkin, Irene Bagaloni, Bruno Vincenzi, Annamaria Ruzzo, Matteo Fassan, Lorenzo Fornaro, Fotios Loupakis, Giuseppe Aprile, Jean Gariépy, Vincenzo Catalano, Sara Lonardi, Michele Prisciandaro
Publikováno v:
Cancers, Vol 12, Iss 2049, p 2049 (2020)
Cancers
Volume 12
Issue 8
Cancers
Volume 12
Issue 8
Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series includin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b406e62e8d6cd67eb065e673eada7ca7
https://hdl.handle.net/11576/2678318
https://hdl.handle.net/11576/2678318
Autor:
Michele Valmasoni, Caterina Vivaldi, Guido Collina, Michela Del Prete, Elena Ongaro, Irene Bagaloni, Giuseppe Perrone, Mauro Magnani, Daniele Santini, Bruno Vincenzi, Giuseppe Aprile, R. Bisonni, D. Sarti, Annamaria Ruzzo, Lorenzo Fornaro, Sara Lonardi, Francesco Graziano, Matteo Fassan, Maria Di Bartolomeo, Vincenzo Catalano, Gianluca Tomasello, Fotios Loupakis, Michele Prisciandaro, P Lorenzini
Publikováno v:
Gastric Cancer
Introduction For energy production, cancer cells maintain a high rate of glycolysis instead of oxidative phosphorylation converting glucose into lactic acid. This metabolic shift is useful to survive in unfavorable microenvironments. We investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43cef4cbe189bb846ce596f0000d1ebf
https://hdl.handle.net/11576/2676120
https://hdl.handle.net/11576/2676120
Autor:
Edoardo Biondi, Francesca Bergamo, Claudia Mucciarini, Vittorina Zagonel, Enzo Veltri, Monica Ronzoni, Eliana Rulli, Claudio Verusio, Luisa Foltran, F. Galli, Daniele Turci, Francesco Graziano, M. Menghi, Alberto Sobrero, Silvia Lazzarelli, Annalisa Bramati, Vincenzo Ricci, Nicoletta Pella, Sara Lonardi, Irene Bagaloni, Francesca Galli, Mauro Magnani, Maria Teresa Ionta, M. Nicolini, Sandro Barni, A. Ruzzo, Bruno Massidda, R. Labianca, L. Frontini, Pietro Sozzi
Publikováno v:
British Journal of Cancer
Background: Dihydropyrimidine dehydrogenase (DPD) catabolises ∼85% of the administered dose of fluoropyrimidines. Functional DPYD gene variants cause reduced/abrogated DPD activity. DPYD variants analysis may help for defining individual patients
Autor:
Sara Lonardi, Nicholas W. Fischer, Michela Del Prete, Donatella Sarti, Maria Di Bartolomeo, Mauro Magnani, Irene Bagaloni, Fotios Loupakis, Annamaria Ruzzo, Bruno Vincenzi, Lorenzo Fornaro, Elena Ongaro, Vincenzo Catalano, Giuseppe Aprile, Jean Gariépy, Michele Prisciandaro, R. Bisonni, Francesco Graziano
Publikováno v:
Journal of Clinical Oncology. 38:e16571-e16571
e16571 Background: Current data support the angiogenic potential of cancer cells with mutant p53 and VEGF-A up-regulation in solid tumors. These findings have renewed interest in the p53 role as a predictive/prognostic factor in cancer therapy. We in
Publikováno v:
Genes & Cancer. 1:197-209
Despite the involvement of genetic alterations in neoplastic cell transformation, it is increasingly evident that abnormal epigenetic patterns, such as those affecting DNA methylation and histone posttranslational modifications (PTMs), play an essent